Aspen Pharmacare surged the most in more than 19 years on Tuesday after the drugmaker said it had reduced its debt and delivered strong cash flows in the second half. 

The rally follows months of share declines as Aspen extended a deadline to close the sale of its infant-formula business, said talks to sell a European business had ended and offered to pay the UK’s National Health Service £8m (R146m)  to settle claims...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.